Free shipping on all orders over $ 500

Brivanib alaninate

Cat. No. M1687

All AbMole products are for research use only, cannot be used for human consumption.

Brivanib alaninate Structure
Synonym:

BMS-582664

Size Price Availability Quantity
10mM*1mL in DMSO USD 130  USD130 In stock
5mg USD 117  USD117 In stock
10mg USD 197  USD197 In stock
50mg USD 700  USD700 In stock
100mg USD 1200  USD1200 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Brivanib alaninate is a prodrug of brivanib (BMS-540215), a potent oral VEGFR-2 inhibitor and is currently in development for the treatment of hepatocellular and colon carcinomas. In vitro and in vivo studies were conducted to characterize the preclinical pharmacokinetics and disposition of brivanib and brivanib alaninate, and antitumor efficacy in mice bearing human xenografts.

Chemical Information
Molecular Weight 441.46
Formula C22H24FN5O4
CAS Number 649735-63-7
Solubility (25°C) DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Narang et al. J Pharm Pharmacol. Reversible and pH-dependent weak drug-excipient binding does not affect oral bioavailability of high dose drugs.

[2] Zhao et al. J Pharm Sci. Acid-catalyzed hydrolysis of BMS-582664: Degradation product identification and mechanism elucidation.

[3] Garrett et al. Br J Cancer. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.

Related VEGFR/PDGFR Products
Conbercept

Conbercept (KH902) is a monoclonal antibody targeting VEGFRA fused to the IGHG1 Fc fragment. Conbercept is produced by the fusion of the second C-LIKE of FLT1 and the third and fourth C-LIKE of KDR with IGHG1 Fc.

SU5208 

SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2).

VEGFR-IN-1 

VEGFR-IN-1 is a potent angiogenesis inhibitor with IC50s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively.

(Z)-Orantinib

(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 µM, respectively.

(Rac)-SAR131675 

(Rac)-SAR131675 is the racemate of SAR131675.

  Catalog
Abmole Inhibitor Catalog




Keywords: Brivanib alaninate, BMS-582664 supplier, VEGFR/PDGFR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.